Although, initially promising effects have been reported in phase 2 trials, more extensive experience has learned that a potential clinical benefit for monotherapies blocking IGF-I or the IGF-IR is only limited to a small subset of patients with specific cancers (sarcoma, Ewing sarcoma non-small cell lung cancer and some other chemotherapy-refractory solid tumors) (38–40), while the majority of studies have been disappointing and have failed to show any clinical benefit in the treatment of cancers (33). The gene discussed is IGF1; the disease is cancer.